Cargando…

Exploration of Benzenesulfonamide-Bearing Imidazole Derivatives Activity in Triple-Negative Breast Cancer and Melanoma 2D and 3D Cell Cultures

Heterocyclic compounds are one of the main groups of organic compounds possessing wide range of applications in various areas of science and their derivatives are present in many bioactive structures. They display a wide variety of biological activities. Recently, more and more attention has been fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Balandis, Benas, Mickevičius, Vytautas, Petrikaitė, Vilma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625351/
https://www.ncbi.nlm.nih.gov/pubmed/34832940
http://dx.doi.org/10.3390/ph14111158
_version_ 1784606400132939776
author Balandis, Benas
Mickevičius, Vytautas
Petrikaitė, Vilma
author_facet Balandis, Benas
Mickevičius, Vytautas
Petrikaitė, Vilma
author_sort Balandis, Benas
collection PubMed
description Heterocyclic compounds are one of the main groups of organic compounds possessing wide range of applications in various areas of science and their derivatives are present in many bioactive structures. They display a wide variety of biological activities. Recently, more and more attention has been focused to such heterocyclic compounds as azoles. In this work, we have synthesized a series of new imidazole derivatives incorporating a benzenesulfonamide moiety in their structure, which then were evaluated for their cytotoxicity against human triple-negative breast cancer MDA-MB-231 and human malignant melanoma IGR39 cell lines by MTT assay. Benzenesulfonamide-bearing imidazole derivatives containing 4-chloro and 3,4-dichlorosubstituents in benzene ring, and 2-ethylthio and 3-ethyl groups in imidazole ring have been determined as the most active compounds. Half-maximal effective concentration (EC(50)) of the most cytotoxic compound was 27.8 ± 2.8 µM against IGR39 cell line and 20.5 ± 3.6 µM against MDA-MB-231 cell line. Compounds reduced cell colony formation of both cell lines and inhibited the growth and viability of IGR39 cell spheroids more efficiently compared to triple-negative breast cancer spheroids.
format Online
Article
Text
id pubmed-8625351
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86253512021-11-27 Exploration of Benzenesulfonamide-Bearing Imidazole Derivatives Activity in Triple-Negative Breast Cancer and Melanoma 2D and 3D Cell Cultures Balandis, Benas Mickevičius, Vytautas Petrikaitė, Vilma Pharmaceuticals (Basel) Article Heterocyclic compounds are one of the main groups of organic compounds possessing wide range of applications in various areas of science and their derivatives are present in many bioactive structures. They display a wide variety of biological activities. Recently, more and more attention has been focused to such heterocyclic compounds as azoles. In this work, we have synthesized a series of new imidazole derivatives incorporating a benzenesulfonamide moiety in their structure, which then were evaluated for their cytotoxicity against human triple-negative breast cancer MDA-MB-231 and human malignant melanoma IGR39 cell lines by MTT assay. Benzenesulfonamide-bearing imidazole derivatives containing 4-chloro and 3,4-dichlorosubstituents in benzene ring, and 2-ethylthio and 3-ethyl groups in imidazole ring have been determined as the most active compounds. Half-maximal effective concentration (EC(50)) of the most cytotoxic compound was 27.8 ± 2.8 µM against IGR39 cell line and 20.5 ± 3.6 µM against MDA-MB-231 cell line. Compounds reduced cell colony formation of both cell lines and inhibited the growth and viability of IGR39 cell spheroids more efficiently compared to triple-negative breast cancer spheroids. MDPI 2021-11-13 /pmc/articles/PMC8625351/ /pubmed/34832940 http://dx.doi.org/10.3390/ph14111158 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Balandis, Benas
Mickevičius, Vytautas
Petrikaitė, Vilma
Exploration of Benzenesulfonamide-Bearing Imidazole Derivatives Activity in Triple-Negative Breast Cancer and Melanoma 2D and 3D Cell Cultures
title Exploration of Benzenesulfonamide-Bearing Imidazole Derivatives Activity in Triple-Negative Breast Cancer and Melanoma 2D and 3D Cell Cultures
title_full Exploration of Benzenesulfonamide-Bearing Imidazole Derivatives Activity in Triple-Negative Breast Cancer and Melanoma 2D and 3D Cell Cultures
title_fullStr Exploration of Benzenesulfonamide-Bearing Imidazole Derivatives Activity in Triple-Negative Breast Cancer and Melanoma 2D and 3D Cell Cultures
title_full_unstemmed Exploration of Benzenesulfonamide-Bearing Imidazole Derivatives Activity in Triple-Negative Breast Cancer and Melanoma 2D and 3D Cell Cultures
title_short Exploration of Benzenesulfonamide-Bearing Imidazole Derivatives Activity in Triple-Negative Breast Cancer and Melanoma 2D and 3D Cell Cultures
title_sort exploration of benzenesulfonamide-bearing imidazole derivatives activity in triple-negative breast cancer and melanoma 2d and 3d cell cultures
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625351/
https://www.ncbi.nlm.nih.gov/pubmed/34832940
http://dx.doi.org/10.3390/ph14111158
work_keys_str_mv AT balandisbenas explorationofbenzenesulfonamidebearingimidazolederivativesactivityintriplenegativebreastcancerandmelanoma2dand3dcellcultures
AT mickeviciusvytautas explorationofbenzenesulfonamidebearingimidazolederivativesactivityintriplenegativebreastcancerandmelanoma2dand3dcellcultures
AT petrikaitevilma explorationofbenzenesulfonamidebearingimidazolederivativesactivityintriplenegativebreastcancerandmelanoma2dand3dcellcultures